Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03226678
Recruitment Status : Active, not recruiting
First Posted : July 24, 2017
Last Update Posted : November 24, 2020
Sponsor:
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : November 26, 2019
Estimated Study Completion Date : July 2022
Certification/Extension First Submitted : July 21, 2020